These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. SDF-1-induced adhesion of monocytes to vascular endothelium is modulated by azelnidipine via protein kinase C inhibition. Takahashi K; Shimokado K; Yoshida M Eur J Pharmacol; 2006 Dec; 552(1-3):162-9. PubMed ID: 17067573 [TBL] [Abstract][Full Text] [Related]
4. Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species. Naito Y; Shimozawa M; Manabe H; Nakabe N; Katada K; Kokura S; Yoshida N; Ichikawa H; Kon T; Yoshikawa T Eur J Pharmacol; 2006 Sep; 546(1-3):11-8. PubMed ID: 16919261 [TBL] [Abstract][Full Text] [Related]
5. Antioxidant effect of a new calcium antagonist, azelnidipine, in cultured human arterial endothelial cells. Shinomiya K; Mizushige K; Fukunaga M; Masugata H; Ohmori K; Kohno M; Senda S J Int Med Res; 2004; 32(2):170-5. PubMed ID: 15080021 [TBL] [Abstract][Full Text] [Related]
6. Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence. Ohyama T; Sato K; Kishimoto K; Yamazaki Y; Horiguchi N; Ichikawa T; Kakizaki S; Takagi H; Izumi T; Mori M Br J Pharmacol; 2012 Feb; 165(4b):1173-87. PubMed ID: 21790536 [TBL] [Abstract][Full Text] [Related]
7. Simultaneous treatment with azelnidipine and olmesartan inhibits apoptosis of Hl-1 cardiac myocytes expressing E334k cMyBPC. Bahrudin U; Ikeda N; Utami SB; Maharani N; Morikawa K; Li P; Sobirin MA; Hasegawa A; Sakata S; Endo R; Rifqi S; Shirayoshi Y; Yamamoto K; Ninomiya H; Hisatome I Drug Res (Stuttg); 2013 Oct; 63(10):515-20. PubMed ID: 23740383 [TBL] [Abstract][Full Text] [Related]
8. Acute effects of intravenous nifedipine or azelnidipine on open-loop baroreflex static characteristics in rats. Yamamoto H; Kawada T; Shimizu S; Kamiya A; Turner MJ; Miyazaki S; Sugimachi M Life Sci; 2015 Apr; 126():37-41. PubMed ID: 25707754 [TBL] [Abstract][Full Text] [Related]
9. Comparative effects of azelnidipine and other Ca2+-channel blockers on the induction of inducible nitric oxide synthase in vascular smooth muscle cells. Ma J; Kishida S; Wang GQ; Meguro K; Imuta H; Oonuma H; Iida H; Jo T; Takano H; Morita T; Nagai R; Nakajima T J Cardiovasc Pharmacol; 2006 Feb; 47(2):314-21. PubMed ID: 16495772 [TBL] [Abstract][Full Text] [Related]
10. Azelnidipine inhibits cultured rat aortic smooth muscle cell death induced by cyclic mechanical stretch. Zhao J; Ozawa K; Kyotani Y; Nagayama K; Ito S; Komatsubara AT; Tsuji Y; Yoshizumi M PLoS One; 2014; 9(7):e102813. PubMed ID: 25032824 [TBL] [Abstract][Full Text] [Related]
11. Effect of azelnidipine and amlodipine on single cell mechanics in mouse cardiomyocytes. Iribe G; Kaihara K; Ito H; Naruse K Eur J Pharmacol; 2013 Sep; 715(1-3):142-6. PubMed ID: 23747592 [TBL] [Abstract][Full Text] [Related]
12. Combination use of immune complexes and a Ca2(+) channel blocker azelnidipine enhances interleukin-12 p40 secretion without T helper type 17 cytokine secretion in human monocyte-derived dendritic cells. Abe T; Fuse I; Narita M; Takahashi M; Aizawa Y Clin Exp Immunol; 2009 Jun; 156(3):405-12. PubMed ID: 19438591 [TBL] [Abstract][Full Text] [Related]
13. Effect of azelnidipine on angiotensin II-mediated growth-promoting signaling in vascular smooth muscle cells. Li JM; Iwai M; Cui TX; Min LJ; Tsuda M; Iwanami J; Suzuki J; Mogi M; Horiuchi M Mol Pharmacol; 2005 May; 67(5):1666-73. PubMed ID: 15695623 [TBL] [Abstract][Full Text] [Related]
14. Calcium channel blockers suppress cytokine-induced activation of human neutrophils. Shima E; Katsube M; Kato T; Kitagawa M; Hato F; Hino M; Takahashi T; Fujita H; Kitagawa S Am J Hypertens; 2008 Jan; 21(1):78-84. PubMed ID: 18091748 [TBL] [Abstract][Full Text] [Related]
15. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Jinno T; Iwai M; Li Z; Li JM; Liu HW; Cui TX; Rakugi H; Ogihara T; Horiuchi M Hypertension; 2004 Feb; 43(2):263-9. PubMed ID: 14707152 [TBL] [Abstract][Full Text] [Related]
16. The actions of azelnidipine, a dihydropyridine-derivative Ca antagonist, on voltage-dependent Ba2+ currents in guinea-pig vascular smooth muscle. Zhu HL; Tomoda T; Aishima M; Ito Y; Teramoto N Br J Pharmacol; 2006 Nov; 149(6):786-96. PubMed ID: 17016499 [TBL] [Abstract][Full Text] [Related]
17. Azelnidipine protects HL-1 cardiomyocytes from hypoxia/reoxygenation injury by enhancement of NO production independently of effects on gene expression. Minato H; Endo R; Kurata Y; Notsu T; Kinugasa Y; Wakimizu T; Tsuneto M; Shirayoshi Y; Ninomiya H; Yamamoto K; Hisatome I; Otsuki A Heart Vessels; 2024 Oct; 39(10):899-908. PubMed ID: 38797744 [TBL] [Abstract][Full Text] [Related]
18. Azelnidipine attenuates cardiovascular and sympathetic responses to air-jet stress in genetically hypertensive rats. Nakamoto M; Ohya Y; Sakima A; Yamazato M; Takishita S Hypertens Res; 2007 Apr; 30(4):359-66. PubMed ID: 17541215 [TBL] [Abstract][Full Text] [Related]
19. Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats. Shokoji T; Fujisawa Y; Kiyomoto H; Rahman M; Sun GP; Fan YY; Kimura S; Kohno M; Abe Y; Nishiyama A Hypertens Res; 2005 Dec; 28(12):1017-23. PubMed ID: 16671342 [TBL] [Abstract][Full Text] [Related]
20. Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells. Matsui T; Yamagishi S; Nakamura K; Kikuchi S; Inoue H Drugs Exp Clin Res; 2005; 31(5-6):215-9. PubMed ID: 16425978 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]